ClinicalTrials.gg
RecruitingNCT07462013POWERUpdated Jun 17, 2026

Lifestyle Interventions to Prevent cOgnitive Deficits in Subjects With Depressive Symptoms: From mEchanisms to Clinical pRactice

An interventional study of Soybean oil (Standard treatment) and Eicosapentaenoic acid (omega-3 fatty acid) in Major Depressive Disorder (MDD), sponsored by National Science and Technology Council, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by National Science and Technology Council, Taiwan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2025, registered Feb 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Depressive Disorder, Major with a site in Taiwan — 13 open to participants now, 13 under way, 6 of them phase 3. Depressive Disorder, Major · Taiwan.

Planned enrollment
33rd of 64
120 · median 128
Started
2025
with 4 others
No phase
26 of 69
3 open now
Primary completion
2028-06
later than 7 of 12 live
Registered
65th of 69
by date

Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, this one is the 33rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2025, is one of 26 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 65th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

13 of the 69 studies in Depressive Disorder, Major with a site in Taiwan are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Depressive Disorder, Major with a site in Taiwan, or all of them as a file.
02

Study summary

POWER project is a randomized, controlled, non-profit study with the primary objective of testing the effectiveness of non-pharmacological interventions-such as physical activity, cognitive training, and dietary supplementation-in reducing depressive symptoms and preventing or delaying cognitive impairments that frequently co-occur in individuals with Major Depressive Disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 50-80 years old
  • Major Depressive Disorder
  • Absence or mild cognitive impairment

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Eicosapentaenoic Acid (EPA)

    3 gram/day

    Dietary Supplement: Eicosapentaenoic acid (omega-3 fatty acid)

  • Placebo comparator
    Placebo

    Soy Bean Oil, 3 gram/day

    Dietary Supplement: Soybean oil (Standard treatment)

Interventions

06

What researchers measure

Primary outcomes

  1. Depressive Symptoms

    The 17-item version (HAMD-17) is used to quantify the severity of depression. A score of ≥18 shows a significant depression level.

    Time frame: Weeks 0, 4, 8, 12, 16, 24

  2. Depressive Symptoms

    The GDS-15 (15-item Geriatric Depression Scale), a score of 5 or higher (≥5) indicates the presence of depression, or "clinically relevant" depressive symptoms.

    Time frame: Weeks 0, 4, 8, 12, 16, 24

  3. Depressive Symptoms

    The 20-item Center for Epidemiological Studies Depression Scale (CES-D) to indicate significant, or "clinical," depressive symptoms is a total score higher than or equal to 16.

    Time frame: Weeks 0, 4, 8, 12, 16, 24

  4. Depressive Symptoms

    The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician-administered scale with a total score range of 0 to 60, where higher scores indicate more severe depression.

    Time frame: Weeks 0, 4, 8, 12, 16, 24

  5. Executive Functioning

    The Trail Making Test (TMT) evaluates cognitive impairment by measuring the time (in seconds) to complete tasks. Higher scores indicate slower, more impaired performance.

    Time frame: Weeks 0, 4, 12, 24

  6. Executive Functioning

    Based on clinical literature, the Reliable Digit Span (RDS)-a raw score sum of the longest string of digits recalled forward and backward-is a common embedded measure of executive functioning and performance validity. Below 7 indicates a need for caution regarding the validity of the patient's cognitive effort or indicates a potential decline in working memory/attention.

    Time frame: Weeks 0, 4, 12, 24

  7. Executive Functioning

    The Modified Wisconsin Card Sorting Test (M-WCST) assesses executive functioning, with higher scores indicating greater dysfunction or impairment.

    Time frame: Weeks 0, 4, 12, 24

  8. General Cognitive Ability and Memory & Attention

    The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) uses age-corrected index scores (Mean=100, SD=15) to identify cognitive impairment. Cutoff points for identifying impairment are set at 1 or 1.5 standard deviations (SD) below the mean.

    Time frame: Weeks 0, 4, 12, 24

  9. Processing Speed

    Commonly used cut-off points for identifying cognitive impairment using the Digit Symbol Substitution Test (DSST) often fall within the range of lower than or equal to 25-35 points.

    Time frame: Weeks 0, 4, 12, 24

Secondary outcomes

  1. Gut microbiome composition

    Gut microbiota composition is primarily measured by analyzing microbial DNA extracted from fecal (stool) samples.

    Time frame: Weeks 0 and 24

  2. Fatty Acids Profiles in Blood

    Fatty acid (FA) profiles in blood (red blood cells) are primarily measured using gas chromatography (GC).

    Time frame: Weeks 0 and 24

07

Study locations

1 of 1 sites recruiting
  • Mind Body Interface Research Center (MBI Lab & Care)
    Taichung, Taichung 404, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 32 months is close to that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 10, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Sep 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462013
Lead sponsor
National Science and Technology Council, Taiwan
Collaborators
IRCCS Centro San Giovanni di Dio Fatebenefratelli, University College Cork
Responsible party
Kuan-Pin (Professor, National Science and Technology Council, Taiwan) — Principal investigator
First posted
Mar 10, 2026
Start date
Oct 1, 2025
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jun 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eicosapentaenoic Acid

Start the discussion